Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, May 14th. Oppenheimer initiated coverage on shares of Capricor Therapeutics in a research note on Friday, May 17th. They set an “outperform” rating and a $14.00 target price on the stock. LADENBURG THALM/SH SH raised their price target on shares of Capricor Therapeutics from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, StockNews.com lowered shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.75.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $4.84 on Tuesday. Capricor Therapeutics has a one year low of $2.68 and a one year high of $8.22. The firm has a market cap of $154.78 million, a price-to-earnings ratio of -5.56 and a beta of 4.00. The firm’s fifty day moving average is $5.37 and its two-hundred day moving average is $5.15.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.20). Capricor Therapeutics had a negative net margin of 89.72% and a negative return on equity of 231.68%. The business had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $10.00 million. As a group, equities research analysts predict that Capricor Therapeutics will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the 1st quarter valued at about $40,000. Jump Financial LLC acquired a new stake in Capricor Therapeutics in the 4th quarter valued at about $258,000. Citigroup Inc. acquired a new stake in Capricor Therapeutics in the 3rd quarter valued at about $211,000. Finally, Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.